The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 78.80
Bid: 77.20
Ask: 77.60
Change: 0.70 (0.90%)
Spread: 0.40 (0.518%)
Open: 78.10
High: 78.80
Low: 77.70
Prev. Close: 78.10
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kerry to acquire Lactase Enzymes Business

12 Dec 2023 16:13

RNS Number : 5363W
Kerry Group PLC
12 December 2023

12 December 2023

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP

Kerry to acquire Lactase Enzymes Business

Kerry Group plc ("Kerry"), the global taste & nutrition company, announces it has entered into a definitive agreement to acquire part of the global lactase enzyme business of Chr. Hansen Holding A/S ("Chr. Hansen") and Novozymes A/S ("Novozymes") (together the "Lactase Enzymes Business") on a carve out basis¹. This acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger approval process.

The Lactase Enzymes Business which includes NOLA® Products, further enhances Kerry's biotechnology solutions capability following the acquisitions of c-LEcta and Enmex². This acquisition adds enzyme technology which helps create lactose-free and sugar reduced dairy products, while preserving their authentic clean taste. Global demand for lactase is being driven by increased awareness of lactose intolerance, while many consumers are also choosing lactose-free for lifestyle and health reasons.

The Lactase Enzymes Business had attributable revenue of approximately ?40m in 2022 with sales in over 50 countries. Total consideration is ?150m subject to routine closing adjustments, with the acquisition expected to close in the first half of 2024.

¹ Acquisition comprises certain trade and assets of Chr. Hansen's global lactase enzyme business and 100% of the share capital of Nuocheng Trillion Food (Tianjin) Co., Ltd, a Chinese subsidiary of Novozymes.

² Acquisition of c-LEcta GmbH completed in March 2022 and Enmex S.A. de C.V. in December 2021.

ENDS

About Kerry

Kerry is a world leading taste and nutrition partner for the food, beverage and pharmaceutical markets. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customers' complex challenges with differentiated solutions. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and to reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerry.com.

CONTACT INFORMATION

Investor Relations

Marguerite Larkin, Chief Financial Officer

+353 66 7182292 | investorrelations@kerry.ie

William Lynch, Head of Investor Relations

+353 66 7182292 | investorrelations@kerry.ie

Media

Catherine Keogh, Chief Corporate Affairs & Brand Officer

+353 45 930188 | corpaffairs@kerry.com

Website

www.kerry.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACQBLBDDDBBDGXD
Date   Source Headline
21st Nov 20237:00 amRNSTransaction in Own Shares
20th Nov 202310:16 amRNSHolding(s) in Company
20th Nov 20237:00 amRNSTransaction in Own Shares
17th Nov 20237:00 amRNSTransaction in Own Shares
16th Nov 20237:00 amRNSTransaction in Own Shares
15th Nov 20237:00 amRNSTransaction in Own Shares
14th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSTransaction in Own Shares
10th Nov 20237:00 amRNSTransaction in Own Shares
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20238:35 amRNSTransaction in Own Shares - Replacement
8th Nov 20237:00 amRNSTransaction in Own Shares
7th Nov 20237:00 amRNSTransaction in Own Shares
6th Nov 20237:00 amRNSTransaction in Own Shares
3rd Nov 20237:05 amRNSTransaction in Own Shares
2nd Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:22 amRNSTotal Voting Rights
1st Nov 20237:00 amRNSKerry Launches EUR300m Share Buyback Programme
26th Oct 20235:03 pmRNSHolding(s) in Company
26th Oct 20237:15 amRNSDirectorate Change
26th Oct 20237:15 amRNSDirectorate Change
26th Oct 20237:00 amRNSQ3 Interim Management Statement 2023
20th Oct 20234:31 pmRNSHolding(s) in Company
2nd Oct 20239:48 amRNSTotal Voting Rights
1st Sep 202310:15 amRNSTotal Voting Rights
2nd Aug 20237:00 amRNSKERRY GROUP INTERIM MANAGEMENT REPORT 2023
1st Aug 202312:32 pmRNSKerry Group acquires Greatang
1st Aug 20239:19 amRNSTotal Voting Rights
3rd Jul 20235:01 pmRNSBlock listing Interim Review
3rd Jul 202310:14 amRNSTotal Voting Rights
12th Jun 20231:42 pmRNSHolding(s) in Company
6th Jun 20233:23 pmRNSHolding(s) in Company
1st Jun 20239:59 amRNSTotal Voting Rights
31st May 20232:46 pmRNSKerry acquires Proexcar S.A.S.
31st May 202312:59 pmRNSHolding(s) in Company
2nd May 202310:07 amRNSTotal Voting Rights
27th Apr 20234:04 pmRNSResult of AGM
27th Apr 20237:00 amRNSQ1 Interim Management Statement 2023
3rd Apr 20239:32 amRNSTotal Voting Rights
27th Mar 20234:30 pmRNSKerry completes Sweet Ingredients Portfolio sale
23rd Mar 202311:48 amRNSNotice of AGM
10th Mar 202310:04 amRNSAnnual Financial Report
9th Mar 20234:16 pmRNSDirector/PDMR Shareholding
9th Mar 20234:12 pmRNSDirector/PDMR Shareholding
9th Mar 20234:11 pmRNSDirector/PDMR Shareholding
1st Mar 202310:47 amRNSTotal Voting Rights
16th Feb 20237:00 amRNSPreliminary Statement of Results 31 December 2022
15th Feb 202311:58 amRNSNotice of Results and AGM
1st Feb 202310:13 amRNSTotal Voting Rights
18th Jan 20237:00 amRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.